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ately and maintained for 10 to 30 years, a vaccination policy where
the low efﬁcacy vaccine is introduced immediately and switched for a
moderate efﬁcacy vaccine when it becomes available 3–8 years later,
and a policy where no vaccine is introduced until the moderate efﬁcacy
vaccine is available.Keywords:
HIV vaccine
Mathematical modelingMathematical modeling has played an important role in the ﬁght
against HIV. Mathematical analysis of a protease inhibitor experiment
enabled the development of the ﬁrst suppressive multi-drug regimens
for treatingHIV (Ho et al., 1995).Mathematicalmodel use in disease ep-
idemiology dates back almost a century (Kermack and McKendrick,
1927). Mathematical modeling allows us to rigorously explore the im-
plications of complex hypotheses. Predictive models are particularly
useful in epidemiology, where multi-armed experiments in vaccination
may be impractical or unethical (Scherer and McLean, 2002).
It is in this tradition thatDimitrov, Kublin, Ramsey andCorey present
an analysis of potential vaccination strategies for HIV in EBioMedicine
(Dimitrov et al., 2015) The search for an effective HIV vaccine has
been long (Fauci and Marston, 2015), (Haynes, 2015). Nearly 30 years
have passed since the ﬁrst HIV vaccine trials, and we have only recently
found the ﬁrst vaccine candidate with any measurable protection
against HIV infection in human subjects (Rerks-Ngarm et al., 2009),
and the reported efﬁcacy of 31% is too low for regulatory approval. It
is likely that incremental advances based on this partial success will
soon result in a vaccine with adequate protection, at least for one
clade of the virus. As Dimitrov and colleagues point out, however, it is
unlikely that a single vaccine will provide the same level of protective
immunity to different HIV clades, which vary between geographic
regions.
If this is the case, then a decisionwill need to bemadewhether to in-
troduce a less effective vaccine, or to wait until a more effective vaccine
becomes available. Dimitrov and colleagues present a mathematical
model of HIV spread through populations, including ranges of possible
population behaviors matched to data from HIV surveillance studies in
San Francisco and South Africa. They compare three vaccine policies: aom.2015.11.009.
. This is an open access article underThe strategies that vaccinated early and then switched are predicted
to be the most effective overall, resulting in a median of 5% fewer total
infections by year 30 when compared with the delayed strategies, a
beneﬁt which was remarkably consistent across different possible pop-
ulation behaviors. This represents billions of dollars in savings measur-
ing antiretroviral therapy costs alone, not to mention the savings in
morbidity and mortality.
These results are a strong argument for early introduction of even
partially effective vaccines, but this is by no means a closed discussion.
If a predictivemodel neglects signiﬁcant effects, then realitywill deviate
from the model predictions. As an example, the authors considered the
possibility that vaccinated patients may reduce their condom use com-
pared with unvaccinated patients. The authors show that a 50% reduc-
tion in condom use among vaccinated patients erases the beneﬁt of
the immediate vaccination strategy, making delayed vaccination
the preferred strategy. This could be moderated through a campaign
aimed at preventing the reduction of condom use by vaccinated per-
sons, but this is a non-trivial hurdle for implementation. The campaign
would have to maximize vaccine coverage while simultaneously em-
phasizing the low protective beneﬁt of the vaccine to maintain high
condom use in the population. Furthermore, the sensitivity of the re-
sults to this one secondary effect emphasizes the need to carefully con-
sider all possible secondary effects, to reduce the chances of missing a
factor which could lead to failure in the ﬁeld. More work is therefore
necessary before deciding on a vaccine policy. Nevertheless, the authors
havemade a compelling case for the potential beneﬁts of deploying low
efﬁcacy vaccines for HIV, an option which would never have been
considered otherwise.References
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